Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Abroad (travel likely)RecruitingPHASE3
Conditions
Allogeneic Stem Cell Transplantation · Lung Allograft Transplantation · Interstitial Lung Disease · Acute Lung Injury · Pulmonary Arterial Hypertension · Cardiovascular Diseases
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (NIH Clinical Center Office of Patient Recruitment (OPR) · ccopr@nih.gov · 800-411-1222
Study leads
Anthony F Suffredini, M.D.
Principal Investigator
National Heart, Lung, and Blood Institute (NHLBI)